Indeed, a BNP reduction to ≤200 ng/L during therapy is a significant predictor of improved survival in patients with AL-CA, while a >30% or >300 ng/L elevation in NT-proBNP or >33% increase in Tn reflect the progression of cardiac impairment (36, 37). This evidence concerns the gene NPPB and cancer.